Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NXT007 versus emicizumab prophylaxis in hemophilia A
PACTR202607919848121Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in hemophilia A comparing NXT007 prophylaxis with Emicizumab prophylaxis (2 arms). Primary endpoint: Non-inferiority of treated bleeds. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zemocimigemicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on PACTR202607919848121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607919848121.